These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 15864119)

  • 1. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.
    Rotger M; Colombo S; Furrer H; Bleiber G; Buclin T; Lee BL; Keiser O; Biollaz J; Décosterd L; Telenti A;
    Pharmacogenet Genomics; 2005 Jan; 15(1):1-5. PubMed ID: 15864119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.
    Heil SG; van der Ende ME; Schenk PW; van der Heiden I; Lindemans J; Burger D; van Schaik RH
    Ther Drug Monit; 2012 Apr; 34(2):153-9. PubMed ID: 22354160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of CYP2B6-516G > T Polymorphism with Plasma Efavirenz Concentration and Depression in HIV-Infected Adults in Northern Thailand.
    Aurpibul L; Chotirosniramit N; Sugandhavesa P; Kosashunhanan N; Thetket S; Supindham T; Piyamongkol W; Supparatpinyo K
    Curr HIV Res; 2012 Dec; 10(8):653-60. PubMed ID: 22950382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients.
    Elens L; Vandercam B; Yombi JC; Lison D; Wallemacq P; Haufroid V
    Pharmacogenomics; 2010 Sep; 11(9):1223-34. PubMed ID: 20860463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.
    Gatanaga H; Hayashida T; Tsuchiya K; Yoshino M; Kuwahara T; Tsukada H; Fujimoto K; Sato I; Ueda M; Horiba M; Hamaguchi M; Yamamoto M; Takata N; Kimura A; Koike T; Gejyo F; Matsushita S; Shirasaka T; Kimura S; Oka S
    Clin Infect Dis; 2007 Nov; 45(9):1230-7. PubMed ID: 17918089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.
    Saitoh A; Sarles E; Capparelli E; Aweeka F; Kovacs A; Burchett SK; Wiznia A; Nachman S; Fenton T; Spector SA
    AIDS; 2007 Oct; 21(16):2191-9. PubMed ID: 18090046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.
    Tsuchiya K; Gatanaga H; Tachikawa N; Teruya K; Kikuchi Y; Yoshino M; Kuwahara T; Shirasaka T; Kimura S; Oka S
    Biochem Biophys Res Commun; 2004 Jul; 319(4):1322-6. PubMed ID: 15194512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children.
    Puthanakit T; Tanpaiboon P; Aurpibul L; Cressey TR; Sirisanthana V
    Antivir Ther; 2009; 14(3):315-20. PubMed ID: 19474465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism.
    Saitoh A; Fletcher CV; Brundage R; Alvero C; Fenton T; Hsia K; Spector SA
    J Acquir Immune Defic Syndr; 2007 Jul; 45(3):280-5. PubMed ID: 17356468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of plasma efavirenz and CYP2B6 polymorphism in southern Chinese.
    To KW; Liu ST; Cheung SW; Chan DP; Chan RC; Lee SS
    Ther Drug Monit; 2009 Aug; 31(4):527-30. PubMed ID: 19531981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.
    Wyen C; Hendra H; Vogel M; Hoffmann C; Knechten H; Brockmeyer NH; Bogner JR; Rockstroh J; Esser S; Jaeger H; Harrer T; Mauss S; van Lunzen J; Skoetz N; Jetter A; Groneuer C; Fätkenheuer G; Khoo SH; Egan D; Back DJ; Owen A;
    J Antimicrob Chemother; 2008 Apr; 61(4):914-8. PubMed ID: 18281305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans.
    Haas DW; Gebretsadik T; Mayo G; Menon UN; Acosta EP; Shintani A; Floyd M; Stein CM; Wilkinson GR
    J Infect Dis; 2009 Mar; 199(6):872-80. PubMed ID: 19239339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.
    Rotger M; Tegude H; Colombo S; Cavassini M; Furrer H; Décosterd L; Blievernicht J; Saussele T; Günthard HF; Schwab M; Eichelbaum M; Telenti A; Zanger UM
    Clin Pharmacol Ther; 2007 Apr; 81(4):557-66. PubMed ID: 17235330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.
    Maganda BA; Minzi OM; Ngaimisi E; Kamuhabwa AA; Aklillu E
    Pharmacogenomics J; 2016 Feb; 16(1):88-95. PubMed ID: 25963334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients.
    Habtewold A; Amogne W; Makonnen E; Yimer G; Riedel KD; Ueda N; Worku A; Haefeli WE; Lindquist L; Aderaye G; Burhenne J; Aklillu E
    J Antimicrob Chemother; 2011 Oct; 66(10):2350-61. PubMed ID: 21846671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana.
    Maseng MJ; Tawe L; Thami PK; Moyo S; Kasvosve I; Novitsky V; Essex M; Russo G; Gaseitsiwe S; Paganotti GM
    Medicine (Baltimore); 2022 Apr; 101(17):e29066. PubMed ID: 35512066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.
    Kwara A; Lartey M; Sagoe KW; Rzek NL; Court MH
    Br J Clin Pharmacol; 2009 Apr; 67(4):427-36. PubMed ID: 19371316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis.
    Ngaimisi E; Mugusi S; Minzi O; Sasi P; Riedel KD; Suda A; Ueda N; Janabi M; Mugusi F; Haefeli WE; Bertilsson L; Burhenne J; Aklillu E
    Clin Pharmacol Ther; 2011 Sep; 90(3):406-13. PubMed ID: 21814190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients.
    Chen J; Sun J; Ma Q; Yao Y; Wang Z; Zhang L; Li L; Sun F; Lu H
    Ther Drug Monit; 2010 Oct; 32(5):573-8. PubMed ID: 20625352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.
    Mukonzo JK; Owen JS; Ogwal-Okeng J; Kuteesa RB; Nanzigu S; Sewankambo N; Thabane L; Gustafsson LL; Ross C; Aklillu E
    PLoS One; 2014; 9(1):e86919. PubMed ID: 24497997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.